[1] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版). 肝脏,2015,20:915-932.
[2] Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B, two double-blind, randomized placebo-controlled sdudies. Kidney Int, 2004, 66:1153-1158.
[3] Liaw YF,Gane E,Leung N,et al. 2 - Year GLOBE trial resuits:telbivudine is superior to lamivudine in patients withchronic hepatitis B.Gastroenterology,2009,136:486 -495.
[4] Gane EJ,Deray G,Liaw YF,et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology,2014,146:138 -146.
[5] Avila C,Iaeufle R,Bao W.CK elevation during chronic hepatitis B(CHB)treatment with telbivudine:experience from the combined GLOBE(NV-02B-007／CLDT 600A2302)and NV-02B-015(015) study clinical safety databasec.Poster #PE 140 Presented at The 19th Asian Pacific Association for the Study of the Liver (APASL);13-16 February,2009,Hong Kong.
[6] Brown CA,Smith F,Laessig KA.Creatine kinase elevations and muscle toxicities associated with chronic teibivudine use in prospective clinical trials.Hepatology,2007,46:655.
[7] Matthews SJ.Telbivudine for the management of chronic hepatitis B virus infection.Clin Ther,2007,29:2635-2653.
[8] Lang CM, Bojunga J, Hoffman WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with Enticavir in patients with impaired liver function. Hepatology,2009,50:2001-2006. |
